Compounds > camptothecin
Page last updated: 2024-08-22

camptothecin and Cachexia

camptothecin has been researched along with Cachexia in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barreto, R; Bonetto, A; Bonewald, LF; Colston, KC; Couch, KE; Couch, ME; Kitase, Y; Matsumoto, T; O'Connell, TM; Pin, F1
Abe, K; Gocho, T; Haruki, K; Onda, S; Sakamoto, T; Takano, Y; Uwagawa, T; Yanaga, K1
Barreto, R; Bonetto, A; Couch, ME; O'Connell, TM; Pin, F1
Barreto, R; Bonetto, A; Gao, H; Liu, Y; Waning, DL; Zimmers, TA1
Mai, M; Takahashi, Y; Yasumoto, K1

Trials

1 trial(s) available for camptothecin and Cachexia

ArticleYear
Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy.
    Anticancer research, 2018, Volume: 38, Issue:4

    Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cachexia; Camptothecin; Combined Modality Therapy; Deoxycytidine; Dietary Supplements; Drug Combinations; Fatty Acids, Omega-3; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Nutritional Support; Organoplatinum Compounds; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Tegafur

2018

Other Studies

4 other study(ies) available for camptothecin and Cachexia

ArticleYear
ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass.
    Scientific reports, 2017, 10-31, Volume: 7, Issue:1

    Topics: Activin Receptors, Type II; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density; Cachexia; Camptothecin; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Femur; Fluorouracil; Induction Chemotherapy; Leucovorin; Male; Mice; Mice, Inbred Strains; Muscle, Skeletal; Muscular Dystrophies

2017
Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism.
    Journal of cachexia, sarcopenia and muscle, 2019, Volume: 10, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Camptothecin; Cell Line, Tumor; Energy Metabolism; Fluorouracil; Glucose; Leucovorin; Liver; Male; Metabolomics; Mice; Muscle Strength; Muscle, Skeletal; Neoplasms; Reactive Oxygen Species; Receptors, LDL

2019
Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs.
    Oncotarget, 2016, Jul-12, Volume: 7, Issue:28

    Topics: Activin Receptors, Type II; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Cachexia; Camptothecin; Cell Line; Colorectal Neoplasms; Flavonoids; Fluorouracil; Humans; Leucovorin; Male; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mice; Mitochondria; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Muscle Fatigue; Muscle, Skeletal; Muscular Atrophy; Myoblasts; Myostatin; Organoplatinum Compounds; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Up-Regulation

2016
Chemotherapy under cachectic conditions and the possibility of cachexia-controlled chemotherapy.
    Oncology reports, 2005, Volume: 14, Issue:1

    Topics: Animals; Antibodies; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Camptothecin; Cell Line, Tumor; Cyclophosphamide; Dose-Response Relationship, Drug; Interleukin-6; Irinotecan; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Survival Analysis; Time Factors; Treatment Outcome

2005